Efficacy of Accelerated Vaccination against Hbv to Achieve Antibody formation in Multiple Sclerosis Patients Receiving Anti-Cd20 Therapy

AIM: Ocrelizumab is a monoclonal antibody that has been approved for use in both relapsing–remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Since ocrelizumab acts on B cells, it also affects humoral immunity, thus reducing the vaccine response. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Koc, Emine Rabia, Turan, Omer Faruk, Saridas, Furkan, Menguc, Bedirhan, Minaz, Sema Nur, Ozkaya, Guven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666883/
https://www.ncbi.nlm.nih.gov/pubmed/38022448
http://dx.doi.org/10.4103/aian.aian_205_23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666883/
https://www.ncbi.nlm.nih.gov/pubmed/38022448
http://dx.doi.org/10.4103/aian.aian_205_23

Ejemplares similares